Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals
T. N. Malla, S. Pandey, I. Poudyal, D. Feliz, M. Noda, G. Phillips, E. Stojkovic, M. Schmidt
Abstract
The SARS coronavirus 2 main protease 3CLpro tailor cuts various essential virus proteins out of long poly-protein translated from the virus RNA. If the 3CLpro is inhibited, the functional virus proteins cannot form and the virus cannot replicate and assemble. Any compound that inhibits the 3CLpro is therefore a potential drug to end the pandemic. Here we show that the diffraction power of 3CLpro crystals is effectively destroyed by Ebselen. It appears that Ebselen may be a widely available, relatively cost effective way to eliminate the SARS coronavirus 2.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies
M. Zmudzinski, W. Rut, … M. Drag·bioRxiv·Aug 30, 2020
- Novel inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
K. Amporndanai, X. Meng, … W. Shang·bioRxiv·Mar 11, 2021
- Ebselen as a highly active inhibitor of PLProCoV2
E. Weglarz-Tomczak, J. M. Tomczak, … S. Brul·bioRxiv·May 17, 2020
- Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
- Discovery of potent inhibitors of PLproCoV2 by screening libraries of selenium-containing compounds
E. Weglarz-Tomczak, J. M. Tomczak, … S. Brul·bioRxiv·May 20, 2020
- Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
N. Drayman, K. A. Jones, … S. Tay·bioRxiv·Aug 31, 2020